Protective effect of Hachimi-jio-gan against the development of pancreatic fibrosis and oxidative damage in Otsuka Long-Evans Tokushima Fatty rats.

Abstract

In our previous study, the polyherbal drug Hachimi-jio-gan was reported to possess a protective effect against the progression of diabetic nephropathy by attenuating glucose toxicity and renal damage with a type 2 diabetic model, Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Based on these findings, this study was undertaken to reveal the effect of Hachimi-jio-gan on pancreatic damage focusing on fibrosis and oxidative stress in type 2 diabetes. OLETF rats were orally administered Hachimi-jio-gan for 32 weeks, and we assessed the changes in the serum glucose level every 8 weeks, as well as those of body weight, and food and water consumption every 4 weeks. In addition, pancreatic wet weight, insulin content, and Western blot analyses of transforming growth factor-beta(1), fibronectin, and nuclear factor-kappaB-related inflammatory enzymes, such as inducible nitric oxide synthesis and cyclooxygenase-2, were also performed in the pancreas. As a consequence, long-term treatment with Hachimi-jio-gan had a hypoglycemic effect, reducing pancreatic atrophy and fibrosis, and ameliorating the oxidative status. Therefore, this may provide evidence that Hachimi-jio-gan is a therapeutic target for preventing the development of pancreatic damage concomitant with hyperglycemia in type 2 diabetes.

• Authors: Noriko Yamabe, Takako Yokozawa
• Journal: Journal of ethnopharmacology (J Ethnopharmacol) Vol. 113 Issue 1 Pg. 91-9 (Aug 15 2007) ISSN: 0378-8741 [Print] Ireland
• PMID: 17606344 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Drugs, Chinese Herbal
• Fibronectins
• Insulin
• Transforming Growth Factor beta1
• hachimijiogan
• Nitric Oxide Synthase Type II
• Cyclooxygenase 2

Topics

• Administration, Oral
• Animals
• Atrophy (prevention & control)
• Blood Glucose (drug effects)
• Blotting, Western
• Cyclooxygenase 2 (metabolism)
• Diabetes Mellitus, Type 2 (complications)
• Disease Models, Animal
• Drugs, Chinese Herbal (pharmacology, therapeutic use)
• Fibronectins (metabolism)
• Fibrosis (etiology, prevention & control)
• Insulin (metabolism)
• Male
• Nitric Oxide Synthase Type II (metabolism)
• Organ Size (drug effects)
• Oxidative Stress (drug effects)
• Pancreatic Diseases (etiology, physiopathology, prevention & control)
• Rats
• Rats, Inbred OLETF
• Rats, Long-Evans
• Transforming Growth Factor beta1 (metabolism)